Related Experiment Video
Updated: Jul 18, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Enhancing Immunogenicity in Metastatic Melanoma: Adjuvant Therapies to Promote the Anti-Tumor Immune Response
Sandra Pelka1, Chandan Guha2,3,4,5
1Department of Development and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Abstract:
Advanced melanoma is an aggressive form of skin cancer characterized by low survival rates. Less than 50% of advanced melanoma patients respond to current therapies, and of those patients that do respond, many present with tumor recurrence due to resistance. The immunosuppressive tumor-immune microenvironment (TIME) remains a major obstacle in melanoma therapy. Adjuvant treatment modalities that enhance anti-tumor immune cell function are associated with improved patient response. One potential mechanism to stimulate the anti-tumor immune response is by inducing immunogenic cell death (ICD) in tumors. ICD leads to the release of damage-associated molecular patterns within the TIME, subsequently promoting antigen presentation and anti-tumor immunity. This review summarizes relevant concepts and mechanisms underlying ICD and introduces the potential of non-ablative low-intensity focused ultrasound (LOFU) as an immune-priming therapy that can be combined with ICD-inducing focal ablative therapies to promote an anti-melanoma immune response.
Insights
Advanced melanoma treatments face challenges due to resistance and immunosuppressive tumor microenvironments. This review explores immunogenic cell death (ICD) and low-intensity focused ultrasound (LOFU) as potential therapies to enhance anti-melanoma immune responses.
Area of Science:
- Oncology
- Immunology
- Biophysics
Background:
- Advanced melanoma exhibits poor survival rates and limited response to current therapies, often complicated by tumor recurrence.
- The tumor-immune microenvironment (TIME) in melanoma is frequently immunosuppressive, hindering effective anti-cancer immunity.
- Enhancing anti-tumor immune cell function through adjuvant therapies is crucial for improving patient outcomes in melanoma.
Purpose of the Study:
- To review the mechanisms of immunogenic cell death (ICD) in stimulating anti-tumor immune responses.
- To introduce non-ablative low-intensity focused ultrasound (LOFU) as a potential immune-priming therapy.
- To explore the combination of LOFU with ICD-inducing therapies for advanced melanoma treatment.
Main Methods:
- Review of existing literature on immunogenic cell death (ICD) and its role in cancer immunology.
- Discussion of the principles and potential applications of low-intensity focused ultrasound (LOFU) in cancer therapy.
- Synthesis of current knowledge to propose a combination therapy strategy.
Main Results:
- Immunogenic cell death (ICD) releases damage-associated molecular patterns, promoting antigen presentation and anti-tumor immunity.
- Non-ablative LOFU shows potential for immune priming within the tumor microenvironment.
- Combining LOFU with focal ablative therapies that induce ICD may enhance the overall anti-melanoma immune response.
Conclusions:
- Immunogenic cell death (ICD) is a promising strategy to overcome the immunosuppressive TIME in advanced melanoma.
- Non-ablative low-intensity focused ultrasound (LOFU) represents a novel approach for immune modulation in cancer therapy.
- Combination therapy utilizing LOFU and ICD-inducing treatments holds potential for improving efficacy in advanced melanoma.
